NCI Basic Research into HIV Structure Pays Off in AIDS Drug Development

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

BETHESDA, Md--NCI research from the 1980s, in which scientists used crystallography to study the structure of the human immunodeficiency virus (HIV), paved the way for development of the current crop of HIV-specific protease inhibitors (see " Early Combination Treatment May Provide HIV Control" for a report on clinical trials of protease inhibitors).

BETHESDA, Md--NCI research from the 1980s, in which scientistsused crystallography to study the structure of the human immunodeficiencyvirus (HIV), paved the way for development of the current cropof HIV-specific protease inhibitors (see " Early CombinationTreatment May Provide HIV Control" for a report on clinicaltrials of protease inhibitors).

Data from crystallization studies were used to develop 3-dimensionalmodels of the enzyme. Researchers were then able to determinethe shape a protease inhibitor must have to "fit" intothe enzyme's active site and inhibit its function.

The coordinates for the 3-dimensional image were deposited inthe Brook-haven National Laboratory database, making the structureavailable to pharmaceutical companies, who then put their drugdesign teams to work to develop novel inhibitors.

George VandeWoude, PhD, special advisor to the director of NCI'sDivision of Basic Sciences, said that the achievement "emphasizesthat basic research is worth the effort."

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Related Content